rslv-132
Recombinant proteinexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2014 (NCT02194400)
Timeline
Indications
Mechanism of action
- Ribonuclease pancreaticACTIVATOR
RNASE1 activator
- RNAHYDROLYTIC ENZYME
RNA hydrolytic enzyme
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297821 ↗
Also known as
- rslv-132
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06440525 | Phase 2 | Sep 1, 2024 | Resolve Therapeutics |
| NCT04944121 | Phase 2 | Jun 25, 2021 | Resolve Therapeutics |
| NCT03247686 | Phase 2 | Feb 1, 2017 | Newcastle University, Resolve Therapeutics, University of Birmingham |
| NCT02660944 | Phase 2 | Jan 1, 2016 | Resolve Therapeutics |
| NCT02194400 | Phase 1 | Jul 1, 2014 | Resolve Therapeutics |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Resolve Therapeutics | For profit | 5 | 5 | 2 | 2014 |
| Newcastle University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Birmingham | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1